Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| MDA-MB-134-VI | Saracatinib | 0.031623 | SRC | MAPK/nRTK | 1.4699 | 0.02402 |
| MDA-MB-134-VI | PF-4708671 | 0.0031623 | p70S6K | PI3K/mTOR | 1.5306 | -0.00002 |
| MDA-MB-134-VI | Dasatinib | 1.0 | BCR/ABL | MAPK/nRTK | 1.5703 | -0.00324 |
| MDA-MB-134-VI | Dasatinib | 0.31623 | BCR/ABL | MAPK/nRTK | 1.7076 | -0.00320 |
| MDA-MB-134-VI | Saracatinib | 0.01 | SRC | MAPK/nRTK | 1.8309 | 0.02283 |
| MDA-MB-134-VI | Saracatinib | 0.1 | SRC | MAPK/nRTK | 1.8592 | 0.03218 |
| MDA-MB-134-VI | Saracatinib | 0.31623 | SRC | MAPK/nRTK | 1.9344 | 0.02326 |
| MDA-MB-134-VI | Saracatinib | 3.1623 | SRC | MAPK/nRTK | 2.4237 | 0.00199 |
| MDA-MB-134-VI | Saracatinib | 1.0 | SRC | MAPK/nRTK | 2.5167 | 0.01029 |
| MDA-MB-134-VI | Alpelisib | 0.31623 | PI3Ka | PI3K/mTOR | 2.6051 | 0.00077 |